deferasirox has been researched along with ciprofloxacin in 6 studies
| Studies (deferasirox) | Trials (deferasirox) | Recent Studies (post-2010) (deferasirox) | Studies (ciprofloxacin) | Trials (ciprofloxacin) | Recent Studies (post-2010) (ciprofloxacin) |
|---|---|---|---|---|---|
| 832 | 136 | 572 | 16,060 | 1,331 | 6,092 |
| Protein | Taxonomy | deferasirox (IC50) | ciprofloxacin (IC50) |
|---|---|---|---|
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | 0.41 | |
| DNA gyrase subunit B | Bacillus subtilis subsp. subtilis str. 168 | 6.3 | |
| DNA gyrase subunit A | Bacillus subtilis subsp. subtilis str. 168 | 6.3 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.31 | |
| DNA gyrase subunit B | Staphylococcus aureus | 4.32 | |
| DNA gyrase subunit A | Escherichia coli K-12 | 0.6845 | |
| DNA gyrase subunit B | Escherichia coli K-12 | 0.5632 | |
| DNA topoisomerase 4 subunit B | Staphylococcus aureus | 6.485 | |
| DNA topoisomerase 4 subunit A | Staphylococcus aureus | 4.8011 | |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 0.41 | |
| DNA gyrase subunit A | Staphylococcus aureus | 4.32 | |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | 0.41 | |
| DNA topoisomerase 4 subunit A | Bacillus subtilis subsp. subtilis str. 168 | 1.7 | |
| DNA topoisomerase 4 subunit B | Bacillus subtilis subsp. subtilis str. 168 | 1.7 | |
| GABA theta subunit | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | 0.41 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cho, HS; Kang, JI; Kim, DM; Kim, HS; Park, CY | 1 |
| Kim, DM; Neupane, GP | 1 |
1 review(s) available for deferasirox and ciprofloxacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for deferasirox and ciprofloxacin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Deferasirox plus ciprofloxacin combination therapy after rapid diagnosis of Vibrio vulnificus sepsis using real-time polymerase chain reaction.
Topics: Aged; Anti-Bacterial Agents; Benzoates; Ciprofloxacin; Deferasirox; DNA, Bacterial; Drug Therapy, Combination; Female; Hemochromatosis; Humans; Polymerase Chain Reaction; Sepsis; Triazoles; Vibrio Infections; Vibrio vulnificus | 2008 |
In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus.
Topics: Anti-Bacterial Agents; Benzoates; Chelating Agents; Ciprofloxacin; Deferasirox; Drug Synergism; Hospitals; Humans; Microbial Sensitivity Tests; Microbial Viability; Republic of Korea; Time Factors; Triazoles; Vibrio Infections; Vibrio vulnificus | 2010 |